Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Cellnovo    CLNV   FR0012633360

CELLNOVO

(CLNV)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Cellnovo : announces the CE marking of the first Bluetooth and Android-enabled micro-pump for insulin delivery

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/13/2017 | 01:14am EDT

Press release

Cellnovo announces the CE marking of the first Bluetooth and

AndroidTM-enabled micro-pump for insulin delivery

Adoption of best-in-class wireless communication technology and standard mobile operating system opens door to interoperability with other connected devices

Paris, France, December 13, 2017 - Cellnovo Group ("Cellnovo" or the "Company" - CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces the achievement of an industry-first, with the CE marking of its next-generation mobile diabetes management system, making it the first insulin delivery platform to use Bluetooth Low Energy and AndroidTM. The use of a best-in-class wireless communication technology and a standard mobile operating system will further enable interoperability with other e-health platforms, including artificial pancreas projects.

This industry-first adds to the Cellnovo System's unique value proposition as the first and only e-connected micro-pump, which provides real time data to patients and clinicians.

The Company's next-generation system, the Cellnovo System with AndroidTM, builds upon the current system in three main aspects:

  • The adoption of standard technologies will facilitate the interoperability of the Cellnovo System with other connected objects for health and well-being. The next-generation system will thus be capable of communicating with devices such as continuous glucose meters, blood glucose meters, fitness trackers, and smart watches, providing a holistic vision of the patient's health. These innovations provide Cellnovo with a best-in-class platform to be used for the Company's future artificial pancreas and automated insulin delivery (AID) product lines.

  • The Cellnovo micro-pump will communicate wirelessly with the touchscreen handset using Bluetooth Low Energy, a standard communication technology dedicated to connected objects. This technology guarantees the quality of communications while significantly reducing energy consumption.

  • The use of the AndroidTM operating system improves the performance of Cellnovo's proprietary touchscreen handset.

Sophie Baratte, Chief Executive Officer of Cellnovo, comments: "We are pleased to announce the CE marking of our next generation mobile diabetes management system. With this next generation system, Cellnovo is now ready for the future of healthcare. Connected devices are a gateway to personalised health management and allow Cellnovo to acquire a platform adapted to future artificial pancreas products. This achievement marks an important milestone in our mission to empower patients and enable them to have greater self-management of chronic diseases like diabetes.

Javaid Masoud, Chief Technology Officer of Cellnovo, comments: "We are proud of this important milestone in Cellnovo's R&D roadmap. Today, we are seeing a rapid convergence of medical devices with lifestyle products such as connected watches and activity trackers. As the first to adopt Bluetooth

1 / 2

Low Energy for a micro-pump used for continuous insulin delivery alongside a proprietary handset that uses the AndroidTM mobile operating system, Cellnovo is positioned to be a major player in this domain."

●●●

About Cellnovo (Euronext: CLNV)

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems.

For more information go to www.cellnovo.com

About the Cellnovo Diabetes Management System

Compact, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with a blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time.

Cellnovo is listed on Euronext, Compartment C

ISIN: FR0012633360 - Ticker: CLNV)

Cellnovo

NewCap

NewCap

Chief Executive Officer

Investor Relations

Media Relations in France

Sophie Baratte

Tristan Roquet Montégon

Nicolas Merigeau

investors@cellnovo.com

+ 33 1 44 71 00 16

+ 33 1 44 71 94 98

cellnovo@newcap.eu

cellnovo@newcap.eu

2 / 2

Cellnovo SA published this content on 13 December 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 13 December 2017 06:13:09 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELLNOVO
04/12CELLNOVO GROUP SA : annual earnings release
03/26CELLNOVO : announces the initiation of collective proceedings regarding its UK s..
PU
01/14CELLNOVO : Drawing of a second tranche of financing from Kreos Capital. Revision..
PU
2018Insulin Delivery Devices Market to 2023 - Top Key Players Novo, Nordisk, Sano..
AQ
2018CELLNOVO GROUP SA : quaterly sales release
2018CELLNOVO : Half-year results
CO
2018CELLNOVO : Press Release
CO
2018CELLNOVO : Annual results
CO
2018CELLNOVO : 1st quarter earnings
CO
2017CELLNOVO : announces the CE marking of the first Bluetooth and Android-enabled m..
PU
More news
Financials (€)
Chart CELLNOVO
Duration : Period :
Cellnovo Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target
EPS Revisions
Managers
NameTitle
Sophie Baratte Chief Executive Officer & Director
John L. Brooks Chairman
Chris Townsend Chief Operating Officer
Erwan Martin Chief Financial Officer
Julian Shapley Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CELLNOVO-90.20%0
SNAP INC153.36%15 665
SEA LTD (ADR)164.66%11 317
ANGI HOMESERVICES INC-9.65%7 127
GRUBHUB INC-8.66%5 739
MOMO INC (ADR)30.65%5 700